Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial of TG-4010 in combination with immune checkpoint inhibitors and chemotherapy in first line, stage IV non-small cell lung cancer patients with tumor cells expressing low or undetectable levels of PD-L1

Next Previous
Trial Profile

A phase I/II trial of TG-4010 in combination with immune checkpoint inhibitors and chemotherapy in first line, stage IV non-small cell lung cancer patients with tumor cells expressing low or undetectable levels of PD-L1

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TG 4010 (Primary) ; Immunomodulators
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Transgene

Most Recent Events

  • 12 Dec 2019 According to a Transgene media release, status changed from planning to withdrawn prior to enrolment, as company has taken the decision to stop further development of TG4010.
  • 20 Mar 2017 According to a Transgene media release, company is in prospective discussion with a pharma to conduct this trial and first patient expected to be enrolled towards the end of 2017 in this trial.
  • 05 Sep 2016 According to a Transgene media release, phase II trial is expected to be initiated in first half of 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top